Antagonist-elicited cannabis withdrawal in humans

Journal of Clinical Psychopharmacology

Volumn 31, Issue 5, 2011, Pages 603-612

  Gorelick, David A ^a   Goodwin, Robert S ^a   Schwilke, Eugene ^a   Schwope, David M ^a   Darwin, William D ^a   Kelly, Deanna L ^b   McMahon, Robert P ^b   Liu, Fang ^b   Ortemann Renon, Catherine ^c   Bonnet, Denis ^c   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c SANOFI   (France)

Author keywords

Antagonist; cannabis; marijuana; rimonabant; withdrawal

Indexed keywords

11 HYDROXYDRONABINOL; PLACEBO; RIMONABANT;

ADULT; ARTICLE; BLOOD PRESSURE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; HEART RATE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; MARIJUANA ABUSE; MASS SPECTROMETRY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SUBSTANCE WITHDRAWAL SYNDROME; TETRAHYDROCANNABINOL; YOUNG ADULT;

EID: 80052435605     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31822befc1     Document Type: Article

References (35)

1. Basavarajappa BS. The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem. 2007;7:769-779. (Pubitemid 47304939)
2. De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab. 2009;23:1-15.
3. Farhang B, Diaz S, Tang SL, et al. Sex differences in the cannabinoid regulation of energy homeostasis. Psychoneuroendocrinology. 2009;34(suppl 1):S237-S246.
4. Janero DR, Makriyannis A. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009;14:43-65.
5. Orgado JM, Fernandez-Ruiz J, Romero J. The endocannabinoid system in neuropathological states. Int Rev Psychiatry. 2009;21:172-180.
6. Pacher P, Mukhopadhyay P, Mohanraj R, et al. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. Hypertension. 2008;52:601-607.
7. Solinas M, Goldberg SR, Piomelli D. The endocannabinoid system in brain reward processes. Br J Pharmacol. 2008;154:369-383. (Pubitemid 351670594)
8. Beardsley PM, Thomas BF, McMahon LR. Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders. Int Rev Psychiatry. 2009;21:134-142.
9. Jagerovic N, Fernandez-Fernandez C, Goya P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr Top Med Chem. 2008;8:205-230. (Pubitemid 351795770)
10. Lee HK, Choi EB, Pak CS. The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem. 2009;9:482-503.
11. Butler H, Korbonits M. Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol. 2009;161:655-662.
12. Le Foll B, Forget B, Aubin HJ, et al. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol. 2008;13:239-252. (Pubitemid 351692986)
13. Morrison MF, Ceesay P, Gantz I, et al. Randomized, controlled, double-blind trial of taranabant for smoking cessation. Psychopharmacology (Berl). 2010;209:245-253.
14. Scheen AJ, Paquot N. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Pract Res Clin Endocrinol Metab. 2009;23:103-116.
15. Soyka M, Koller G, Schmidt P, et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol. 2008;28:317-324.
16. United Nations Office on Drugs and Crime. World Drug Report 2009. Vienna, Austria: United Nations Office on Drugs and Crime; 2009. Report No. E.09.XI.12.
17. Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handb Exp Pharmacol. 2005;168:691-717.
18. Stewart J, McMahon LR. Rimonabant-induced $9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs. J Pharmacol Exp Ther. 2010;334:347-356.
19. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid- oriented clinical research after CB1 antagonists. Psychopharmacology (Berl). 2009;205:171-174.
20. Budney AJ, Hughes JR, Moore BA, et al. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry. 2004;161:1967-1977. (Pubitemid 39441395)
21. Haney M, Ward AS, Comer SD, et al. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology (Berl). 2001;155:171-179. (Pubitemid 32417826)
22. Huestis MA, Sampson AH, Holicky BJ, et al. Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther. 1992;52:31-41.
23. Huestis MA, Gorelick DA, Heishman SJ, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch Gen Psychiatry. 2001;58:322-328. (Pubitemid 32299527)
24. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann N Y Acad Sci. 1976;282:221-239. (Pubitemid 8023834)
25. Cyr JJ, Kenna-Foley JM, Peacock E. Factor structure of the SCL-90-R: is there one? J Pers Assess. 1985;49:571-578.
26. Ellis BW, Johns MW, Lancaster R, et al. The St. Mary's Hospital Sleep Questionnaire: a study of reliability. Sleep. 1981;4:93-97. (Pubitemid 11152405)
27. Heishman SJ, Evans RJ, Singleton EG, et al. Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend. 2009;102:35-40.
28. Lowe RH, Karschner EL, Schwilke EW, et al. Simultaneous quantification of $9-tetrahydrocannabinol, 11-hydroxy-$9-tetrahydrocannabinol, and 11-nor-$9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impactYmass spectrometry. J Chromatogr A. 2007;1163:318-327. (Pubitemid 47247721)
29. Haney M, Ward AS, Comer SD, et al. Abstinence symptoms following oral THC administration to humans. Psychopharmacology (Berl). 1999;141:385-394. (Pubitemid 29190007)
30. Schwilke EW, Schwope DM, Karschner EL, et al. $9- tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem. 2009;55:2180-2189.
31. Turpault S, Kanamaluru V, Lockwood GF, et al. Rimonabant pharmacokinetics in healthy and obese subjects. Clin Pharmacol Ther. 2006;79:P50.
32. Huestis MA, Boyd SJ, Heishman SJ, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl). 2007;194:505-515. (Pubitemid 47492992)
33. Need AB, Davis RJ, Alexander-Chacko JT, et al. The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. Psychopharmacology (Berl). 2006;184:26-35. (Pubitemid 43005754)
34. Rinaldi-Carmona M, Barth F, Heaulme M, et al. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 1995;56:1941-1947.
35. Rinaldi-Carmona M, Barth F, Heaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240-244. (Pubitemid 24268029)